Data from a phase II trial designed to investigate the efficacy of the pan αv-integrin inhibitor abituzumab in patients with metastatic CRPC (mCRPC) reveal that abituzumab, compared with luteinizing hormone receptor agonists/antagonists has no effect on progression-free survival (PFS). However, patients receiving abituzumab had a significant reduction in the progression of bone metastasis after a follow-up duration of 24 months. This effect merits further investigation.
References
Hussain, M. et al. Differential effect on bone lesions of targeting integrins: randomized phase II trial of abituzumab in patients with metastatic castration-resistant prostate cancer. Clin. Cancer Res, http://dx.doi.org/10.1158/1078-0432.CCR-15-2512 (2016)
Rights and permissions
About this article
Cite this article
Sidaway, P. Integrin inhibitors active against bone metastases. Nat Rev Urol 13, 182 (2016). https://doi.org/10.1038/nrurol.2016.42
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2016.42